The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Mechanisms of fatty acid-induced inhibition of glucose uptake.
Boden, G., Chen, X., Ruiz, J., White, J. V., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117252 · Cited by 3,705
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Homocysteine and Risk of Ischemic Heart Disease and Stroke: A Meta-analysis
Homocysteine Studies Collaboration (2002) · JAMA · doi:10.1001/jama.288.16.2015 · Cited by 2,059
Lee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., & Gonzalez, F. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3012 · Cited by 1,655
Band Horwitz, S. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90048-b · Cited by 740
Guerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.-M., Winegar, D. A., Willson, T. M., Fruchart, J.-C., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.22.16638 · Cited by 605
Laurin, J., Lindor, K. D., Crippin, J. S., Gossard, A., Gores, G. J., Ludwig, J., Rakela, J., & McGill, D. B. (1996) · Hepatology · doi:10.1002/hep.510230624 · Cited by 566
Central Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in Mice
Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., & Leclercq, I. (2003) · Hepatology · doi:10.1053/jhep.2003.50307 · Cited by 476
Hashimoto, T., Cook, W. S., Qi, C., Yeldandi, A. V., Reddy, J. K., & Rao, M. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910350199 · Cited by 444
Fruchart, J.-C., Duriez, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00007 · Cited by 425
Ip, E., Farrell, G., Hall, P., Robertson, G., & Leclercq, I. (2004) · Hepatology · doi:10.1002/hep.20170 · Cited by 383
A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
Basaranoglu, M., Acbay, O., & Sonsuz, A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80243-8 · Cited by 305
Non-alcoholic fatty liver: another feature of the metabolicsyndrome?
Cortez-Pinto, H., Camilo, M. E., Baptista, A., De Oliveira, A. G., & De Moura, M. C. (1999) · Clinical Nutrition · doi:10.1016/s0261-5614(99)80015-6 · Cited by 301
Chou, C. J., Haluzik, M., Gregory, C., Dietz, K. R., Vinson, C., Gavrilova, O., & Reitman, M. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202449200 · Cited by 197
PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats
Toyama, T., Nakamura, H., Harano, Y., Yamauchi, N., Morita, A., Kirishima, T., Minami, M., Itoh, Y., & Okanoue, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.110 · Cited by 172
PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats
外山, 哲. (2005) · Medical Entomology and Zoology · Cited by 142
Serum homocysteine increases after therapy with fenofibrate or bezafibrate
Dierkes, J., Westphal, S., & Luley, C. H. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02153-4 · Cited by 141
Fenofibrate prevents and reduces body weight gain and adiposity in diet‐induced obese rats
Mancini, F. P., Lanni, A., Sabatino, L., Moreno, M., Giannino, A., Contaldo, F., Colantuoni, V., & Goglia, F. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02146-9 · Cited by 138
Nonalcoholic steatohepatitis: pathologic features and differential diagnosis
Brunt, E. M. (2005) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2006.04.002 · Cited by 101
Inoue, I., Noji, S., Awata, T., Takahashi, K., Nakajima, T., Sonoda, M., Komoda, T., & Katayama, S. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00249-5 · Cited by 100
Role of muscle in triglyceride metabolism
Goodpaster, B. H., & Kelley, D. E. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199806000-00008 · Cited by 84
Idzior−Waluś, B., Sieradzki, J., Rostworowski, W., Zdzienicka, A., Kawalec, E., Wójcik, J., Zarnecki, A. F., & Blane, G. F. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00734.x · Cited by 83
Fenofibrate: Metabolic and Pleiotropic Effects
Tsimihodimos, V., Miltiadous, G. A., Daskalopoulou, S. S., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Vascular Pharmacology · doi:10.2174/1570161052773942 · Cited by 77
Dana, S. L., Hoener, P. A., Bilakovics, J. M., Crombie, D. L., Ogilvie, K. M., Kauffman, R. F., Mukherjee, R., & Paterniti, J. R. (2001) · Metabolism · doi:10.1053/meta.2001.24870 · Cited by 46
Rao, M. S., Papreddy, K., Musunuri, S., & Okonkwo, A. M. (2002) · PubMed · Cited by 44
Guéraud, F., Alary, J., Costet, P., et al. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33350-2 · Cited by 43
Frederiksen, K. S., Wulff, E. M., Wassermann, K., Sauerberg, P., & Fleckner, J. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0300317 · Cited by 27
Fibrates for treatment of the metabolic syndrome
Maki, K. C. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0115-5 · Cited by 24
Research works printed but not linked: 2
- Damci, 2003, Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia, Eur J Int Med, 14, 357, 10.1016/S0953-6205(03)90001-X · doi:10.1016/s0953-6205(03)90001-x
- Rawat, 1975, Effect of clofibrate on cholesterol and lipid metabolism in ethanol-treated mice, Res Commun Chem Pathol Pharmacol, 10, 501
Cited by
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Metadata
- Authors
- Fernández-Miranda, C., Pérez-Carreras, M., Colina, F., López-Alonso, G., Vargas, C., & Solís-Herruzo, J. A.
- Venue
- Digestive and Liver Disease
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 40
- Issue
- 3
- Pages
- 200-205
- ISSN
- 1590-8658 (ISSN-L)
- OpenAlex
- W2082702559
- Cited by
- 256
- References
- 34
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.